BE742205A - - Google Patents
Info
- Publication number
- BE742205A BE742205A BE742205DA BE742205A BE 742205 A BE742205 A BE 742205A BE 742205D A BE742205D A BE 742205DA BE 742205 A BE742205 A BE 742205A
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2416068 | 1968-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE742205A true BE742205A (cg-RX-API-DMAC7.html) | 1970-05-25 |
Family
ID=11212294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE742205D BE742205A (cg-RX-API-DMAC7.html) | 1968-11-26 | 1969-11-25 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3660322A (cg-RX-API-DMAC7.html) |
| AT (1) | AT290542B (cg-RX-API-DMAC7.html) |
| BE (1) | BE742205A (cg-RX-API-DMAC7.html) |
| BR (1) | BR6914433D0 (cg-RX-API-DMAC7.html) |
| CH (1) | CH523892A (cg-RX-API-DMAC7.html) |
| DE (1) | DE1958515B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK123239B (cg-RX-API-DMAC7.html) |
| ES (1) | ES373909A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2024241B1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1231959A (cg-RX-API-DMAC7.html) |
| IE (1) | IE33406B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL33393A (cg-RX-API-DMAC7.html) |
| NL (1) | NL147140B (cg-RX-API-DMAC7.html) |
| NO (1) | NO123430B (cg-RX-API-DMAC7.html) |
| SE (1) | SE360659B (cg-RX-API-DMAC7.html) |
| YU (1) | YU33286B (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE31617E (en) * | 1972-02-04 | 1984-06-26 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
| DE3815767A1 (de) * | 1988-05-09 | 1989-11-23 | Karl Niggemeier | Abhefter fuer einzelblaetter |
| WO1993022292A1 (en) * | 1992-05-07 | 1993-11-11 | Merck & Co., Inc. | New quinazolines as inhibitors of hiv reverse transcriptase |
| US6124302A (en) * | 1997-04-09 | 2000-09-26 | Dupont Pharmaceuticals | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors |
| JP2002509922A (ja) * | 1998-03-27 | 2002-04-02 | デュポン ファーマシューティカルズ カンパニー | ４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリンチオン誘導体、それらの調製法、およびｈｉｖ逆転写酵素阻害剤としてのそれらの使用 |
-
1969
- 1969-11-13 NL NL696917085A patent/NL147140B/xx unknown
- 1969-11-21 US US878880A patent/US3660322A/en not_active Expired - Lifetime
- 1969-11-21 IL IL33393A patent/IL33393A/en unknown
- 1969-11-21 YU YU2922/69A patent/YU33286B/xx unknown
- 1969-11-21 DE DE19691958515 patent/DE1958515B2/de active Granted
- 1969-11-21 FR FR696940093A patent/FR2024241B1/fr not_active Expired
- 1969-11-21 IE IE1581/69A patent/IE33406B1/xx unknown
- 1969-11-21 AT AT1088169A patent/AT290542B/de not_active IP Right Cessation
- 1969-11-24 BR BR214433/69A patent/BR6914433D0/pt unknown
- 1969-11-24 SE SE16089/69A patent/SE360659B/xx unknown
- 1969-11-24 NO NO4649/69A patent/NO123430B/no unknown
- 1969-11-24 DK DK621469AA patent/DK123239B/da unknown
- 1969-11-24 GB GB1231959D patent/GB1231959A/en not_active Expired
- 1969-11-25 BE BE742205D patent/BE742205A/xx unknown
- 1969-11-25 CH CH1754469A patent/CH523892A/de not_active IP Right Cessation
- 1969-11-25 ES ES373909A patent/ES373909A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BR6914433D0 (pt) | 1973-02-22 |
| AT290542B (de) | 1971-06-11 |
| IE33406L (en) | 1970-05-26 |
| YU292269A (en) | 1976-03-31 |
| IL33393A0 (en) | 1970-01-29 |
| YU33286B (en) | 1976-08-31 |
| DE1958515B2 (de) | 1976-06-24 |
| GB1231959A (cg-RX-API-DMAC7.html) | 1971-05-12 |
| FR2024241B1 (cg-RX-API-DMAC7.html) | 1973-07-13 |
| NL6917085A (cg-RX-API-DMAC7.html) | 1970-05-28 |
| IL33393A (en) | 1973-04-30 |
| NL147140B (nl) | 1975-09-15 |
| FR2024241A1 (cg-RX-API-DMAC7.html) | 1970-08-28 |
| CH523892A (de) | 1972-06-15 |
| DK123239B (da) | 1972-05-29 |
| US3660322A (en) | 1972-05-02 |
| DE1958515A1 (de) | 1970-07-09 |
| SE360659B (cg-RX-API-DMAC7.html) | 1973-10-01 |
| IE33406B1 (en) | 1974-06-12 |
| ES373909A1 (es) | 1972-08-16 |
| NO123430B (cg-RX-API-DMAC7.html) | 1971-11-15 |